Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

This is the first of four policy briefings from the Biomodifying technologies project. In this briefing, the team set out our understanding of a 'good clinical target' in each of the areas studied: gene editing, induced pluripotent stem cells (iPSCs) and 3D bioprinting.


Internet publication


Publication Date